| Previous Close | 0.155 |
| Open | 0.155 |
| Bid | 0.160 x 0 |
| Ask | 0.170 x 0 |
| Day's Range | 0.155 - 0.165 |
| 52 Week Range | 0.150 - 1.090 |
| Volume | 525,690 |
| Avg. Volume | 273,661 |
| Market Cap | 13.19M |
| Beta (3Y Monthly) | -4.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.268 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CannX is a meeting of global leaders in all areas of medical cannabis where the latest scientific and clinical research, agricultural practices, innovation, and business opportunities are explored. Israel has been one of the world's leading countries for medical cannabis research.
The Masterclass Medicinal Cannabis® is an exclusive education seminar hosted by Dr. Arno Hazekamp, the former Head of Research and Education for Bedrocan BV, a multinational company that has been growing and supplying pharmaceutical grade medicinal cannabis since the early 1980s. Since its start in 2011, the Masterclass has provided a one week intensive and in-depth learning environment focused on providing science-based information on all aspects of cannabis as a plant-based medicine.
VANCOUVER, B.C., Oct. 05, 2018 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce along with the Institute.
Under the terms of the MOU, both companies wish to collaborate in a structured, scientific manner with respect to formally identifying and cooperating on the advancement of medical cannabis strains or cultivars as well as to jointly develop, commercialize and patent protect medicinal products to treat specific diseases and chronic conditions. Veritas’ CEO, Dr. Lui Franciosi stated, “With Agrima’s superior breeding and cultivating practices, our scientists at Cannevert Therapeutics Ltd. (“CTL”) will be able to further research for both companies by infusing CTL’s pharmacological knowledge and practices in discovering and developing proprietary products that have consistent and optimal clinical effects. This will be a great partnership for the science and business of medical cannabis”.
VANCOUVER, British Columbia, Sept. 19, 2018-- Veritas Pharma Inc. is pleased to provide a corporate update on its activities, milestones over the first three quarters of 2018, and strategies for growth ...
3 Carbon will advise them on quality assurance standards for light hydrocarbon-based manufacturing and extraction methods. CannabisWise is an accreditation program established by the BC based National Institute for Cannabis Health and Education (NICHE) earlier this year in response to Canada’s plan to legalize cannabis. 3 Carbon Extractions CEO Phillip Kwong said, “We are excited to be collaborating with this exciting initiative.
VANCOUVER, British Columbia, Sept. 13, 2018 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that the.
VANCOUVER, British Columbia, Sept. 11, 2018-- Veritas Pharma Inc. is pleased to announce that 3 Carbon Extractions Inc., an industry leader in regulatory compliant cannabis hydrocarbon extraction solutions, ...
VANCOUVER, British Columbia, Sept. 05, 2018-- Veritas Pharma Inc. is pleased to announce that its subsidiary, 3 Carbon Extractions Inc., has completed an exclusive marketing rights relationship with ExtractionTek ...
Lui Franciosi commented: “We are very pleased to welcome Mr. Roseborough to Veritas’ Board of Directors. Mr. Roseborough brings a wealth of talent and expertise to the Company. He’s currently the CEO of SunVault Energy Inc. (SVLT) in Kelowna, B.C., which focuses on bringing cost effective energy generation and storage to the solar industry. He previously held the position as a Start-up Lead Executive for Dow Corning’s $1.2 billion Semiconductor plant in Clarksville, Tennessee.
Under the terms of the Agreement as previously announced on April 16, 2018, Veritas has invested $300,000 US into 3 Carbon and issued 1,500,000 common shares of Veritas at a deemed price of $0.40 per share to the shareholders of 3 Carbon. The cash consideration will be used to build a scalable extraction facility at a location to be determined by the board of Veritas.
VANCOUVER, British Columbia, Aug. 15, 2018-- Veritas Pharma Inc. is pleased to announce that it has signed a Memorandum of Understanding with IsCann Group Limited located in Be'er Tuvya, Israel with the ...
VANCOUVER, British Columbia, Aug. 13, 2018-- Veritas Pharma Inc. is pleased to announce that it has entered into a Memorandum of Understanding with the Chamber of Commerce, Industry, Services and Tourism ...
VANCOUVER, British Columbia, Aug. 08, 2018-- Veritas Pharma Inc. is pleased to announce that Clearstream Banking, a major central securities depository based in Frankfurt, Germany, which announced on June ...
VANCOUVER, British Columbia, July 27, 2018-- Veritas Pharma Inc. is pleased to announce that effective June 25, 2018, it cancelled a total of 3,272,000 incentive stock options granted under the Company’ ...